Drug Utilization Review (DUR) is a Foundational Component of the Pharmacist’s Standard of Care | August 7, 2025
Overview
In this session, we will explore the heightened importance of DUR in the context of pharmacy compounding, outline best practices for conducting thorough reviews, and examine potential drug interactions associated with commonly compounded therapies
Intended audience
- Pharmacists & Pharmacy Technicians
Learning Objectives
Pharmacists and Pharmacy Technicians
- Discuss the OBRA 1990 requirement for drug utilization review
- Explain the importance of performing a prospective DUR
- Recognize some potential interactions with commonly compounded preparations
- Identify the steps to perform a DUR and perform interventions
Hardware/software requirements
We will be using Zoom for this webinar - full system requirements can be found here. You can download the Zoom client here.
Web browser |
| ||
Internet connection |
| ||
Misc |
| ||
Hardware | Minimum | Recommended | |
Processor | Single-core 1Ghz or higher | Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent) | |
RAM | N/A | 4 GB |
COPYRIGHT
This webinar is Copyright © Alliance for Pharmacy Compounding 2025.
Kathleen Jackson, RPh, PhD (HC), FAPC | ![]() |
Kathy has over four decades of experience in compounding, beginning with owning and operating her own community pharmacy and later becoming a PCAB Surveyor and independent consultant. She has aided 503(a) and (b) pharmacies with FDA inspections and 483 responses. Kathy is a fellow of IACP (now APC) and a certified sterile compounding trainer. She served two terms on the IACP board, and as the President of the IACP Foundation, as well as chair of the compounding section of the Texas Pharmacy Association. In 2015-2016, she co-authored two IJPC articles on Root Cause Analysis. In 2018, she achieved the CISCI certification from Critical Point for State Board Inspectors. Kathy’s passion lies in helping pharmacies maintain compliance through self-assessment.